[HTML][HTML] Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion

SR Mulay, OP Kulkarni, KV Rupanagudi… - The Journal of …, 2012 - Am Soc Clin Investig
SR Mulay, OP Kulkarni, KV Rupanagudi, A Migliorini, MN Darisipudi, A Vilaysane, D Muruve…
The Journal of clinical investigation, 2012Am Soc Clin Investig
Nephrocalcinosis, acute calcium oxalate (CaOx) nephropathy, and renal stone disease can
lead to inflammation and subsequent renal failure, but the underlying pathological
mechanisms remain elusive. Other crystallopathies, such as gout, atherosclerosis, and
asbestosis, trigger inflammation and tissue remodeling by inducing IL-1β secretion, leading
us to hypothesize that CaOx crystals may induce inflammation in a similar manner. In mice,
intrarenal CaOx deposition induced tubular damage, cytokine expression, neutrophil …
Nephrocalcinosis, acute calcium oxalate (CaOx) nephropathy, and renal stone disease can lead to inflammation and subsequent renal failure, but the underlying pathological mechanisms remain elusive. Other crystallopathies, such as gout, atherosclerosis, and asbestosis, trigger inflammation and tissue remodeling by inducing IL-1β secretion, leading us to hypothesize that CaOx crystals may induce inflammation in a similar manner. In mice, intrarenal CaOx deposition induced tubular damage, cytokine expression, neutrophil recruitment, and renal failure. We found that CaOx crystals activated murine renal DCs to secrete IL-1β through a pathway that included NLRP3, ASC, and caspase-1. Despite a similar amount of crystal deposits, intrarenal inflammation, tubular damage, and renal dysfunction were abrogated in mice deficient in MyD88; NLRP3, ASC, and caspase-1; IL-1R; or IL-18. Nephropathy was attenuated by DC depletion, ATP depletion, or therapeutic IL-1 antagonism. These data demonstrated that CaOx crystals trigger IL-1β–dependent innate immunity via the NLRP3/ASC/caspase-1 axis in intrarenal mononuclear phagocytes and directly damage tubular cells, leading to the release of the NLRP3 agonist ATP. Furthermore, these results suggest that IL-1β blockade may prevent renal damage in nephrocalcinosis.
The Journal of Clinical Investigation